Component
Human cytochrome P450 2A13 / CYP2A13
Human cytochrome P450 2A13 / CYP2A13
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
Recombinant human CYP2A13 converted apigenin to luteolin, with reported substrate S50 of 14 micromolar.
Experimental context and source evidence
- evidence_access
- Indexed primary abstract and publisher-indexed Results; recombinant-enzyme selectivity, not complete human metabolic mass balance.
- experimental_model
- Recombinant human enzyme; not whole-body metabolic flux.
- interpretation_status
- Recorded from source with stated access limits; ungraded, not independent replication.
- limitations
- Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
- nutrient_topic
- Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
- plain_language
- Recombinant human CYP2A13 converted apigenin to luteolin, with reported substrate S50 of 14 micromolar.
- primary_references
- Oxidation of Naringenin, Apigenin, and Genistein by Human Family 1 Cytochrome P450 Enzymes and Comparison of Interaction of Apigenin with Human P450 1B1.1 and Scutellaria P450 82D.1. | https://pubmed.ncbi.nlm.nih.gov/37783573/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11497155/ | https://doi.org/10.1021/acs.chemrestox.3c00229
- source_locator
- Reviewed reference api-cyp2a13-luteolin;
Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 106–112
AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Recombinant human enzyme; not whole-body metabolic flux. · Recorded from source · Recorded from source
### api-cyp2a13-luteolin Recombinant human CYP2A13 converted apigenin to luteolin, with reported substrate S50 of 14 micromolar. Model and exposure: Recombinant human enzyme; not whole-body metabolic flux. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Oxidation of Naringenin, Apigenin, and Genistein by Human Family 1 Cytochrome P450 Enzymes and Comparison of Interaction of Apigenin with Human P450 1B1.1 and Scutellaria P450 82D.1. | 2023 | https://pubmed.ncbi.nlm.nih.gov/37783573/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11497155/ | https://doi.org/10.1021/acs.chemrestox.3c00229 | Access: Indexed primary abstract and publisher-indexed Results; recombinant-enzyme selectivity, not complete human metabolic mass balance.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.